Combinatorial Technology Supervisory Patent Examiner

Slides:



Advertisements
Similar presentations
Technology Center 1600 Training on Writing Rejections Under 35 U.S.C. § 103.
Advertisements

Slides to Accompany Artful Prior Art. Derwent GENESEQ Database Collection of patented DNA sequences –10 or more base pairs Coverage from 1981 Feb. 2001:
Disclaimer: The information provided by the USPTO is meant as an educational resource only and should not be construed as legal advice or written law.
Michael P. Woodward Supervisory Patent Examiner Art Unit 1631 (703) SNiPpetS & Bytes
Patenting Antisense Oligonucleotides and Methods
35 U.S.C. 112, 6th Paragraph Long V. Le SPE, AU 1641 (703)
RESTRICTION PRACTICE POLYNUCLEOTIDES POLYPEPTIDES AND FRAGMENTS Christopher Low / James Housel TC1600 /AU 1653 (703)
Rule 105 Requirements in Plant Patent Applications Bruce Campell Supervisory Patent Examiner Art Unit
Incorporation by Reference
1 ISSUES IN SMALL ORGANIC MOLECULES Michael G. Hartley Supervisory Patent Examiner US Patent & Trademark Office Art Unit
Enablement Issues in the Examination of Antibodies
Filing for a United States Patent “Helpful Hints” U.S. Patent and Trademark Office.
Proteomics Examination Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
Utility and Written Description Steve Kunin Deputy Commissioner for Patent Examination Policy Esther Kepplinger Deputy Commissioner for Patent Operations.
1 Sreeni Padmanabhan SPE – AU 1617 Tel:
Chemical Non-Statutory Double Patenting Examples Daniel Sullivan SPE, Art Unit 1621.
1 35 USC 112, 1 st paragraph enablement Enablement Practice in TC 1600 Deborah Reynolds, SPE
September 14, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December.
35 U.S.C. 112, Sixth Paragraph MPEP 2181 – 2186 Jean Witz Quality Assurance Specialist Technology Center 1600.
Proteomics and “Orphan” Receptors Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
“REACH-THROUGH CLAIMS”
1 Biotechnology Partnership Meeting April 17, 2001 James Martinell Senior Level Examiner Technology Center 1600.
Determination of Obviousness Practice Under the Genus-Species Guidelines and In re Ochiai; In re Brouwer Sreeni Padmanabhan & James Wilson Supervisory.
1 Single Nucleotide Polymorphisms (SNP) Gary Jones SPE, Technology Center 1600 (703)
Restriction Practice for Genus Claims Species Claims Linking Claims and Markush Claims Julie Burke QAS/PM TC1600.
Determining Obviousness under 35 USC 103 in view of KSR International Co. v. Teleflex TC3600 Business Methods January 2008.
Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Examining Issues When.
Issues in Patenting Proteins Jon P Weber, SPE 1657.
Examination Issues: Immunology Yvonne (Bonnie) Eyler Quality Assurance Specialist Technology Center 1600 USPTO (571)
1 Unity of Invention: Biotech Examples TC1600 Special Program Examiner Julie Burke (571)
RESTRICTING BETWEEN PRODUCT and PROCESS INVENTIONS Bruce Campell Supervisory Patent Examiner Art Unit
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
Combinatorial Chemistry and Library Design
1 ANTICIPATION BY INHERENCY IN PRIOR ART James O. Wilson Supervisory Patent Examiner Technology Center 1600 USPTO (571)
Broadening the Scope of the Claims in Gene Therapy Applications Deborah Reynolds Detailee, TCPS
Notice of Proposed Rule Making Affecting Claims That Recite Alternatives 1 Robert Clarke, Director Office of Patent Legal Administration (571)
Restriction & Double Patenting Mojdeh Bahar, J.D., M.A., CLP Chief, Cancer Branch Office of Technology Transfer National Institutes of Health U.S. Department.
Patenting Interfering RNA
U.S. Patent and Trademark Office Technology Center 1600 Michael P. Woodward Unity of Invention: Biotech Examples.
To Restrict or Not To Restrict That Is The Question? Divided We Stand! Or Undivided We Stand!! By Joseph K. McKane SPE, Art Unit 1626.
1 Restriction Practice Updates Julie Burke TC1600 Quality Assurance Specialist
Stereochemistry and Christopher Low
July 18, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December 10,
1 Written Description Analysis and Capon v. Eshhar Jeffrey Siew Supervisory Patent Examiner AU 1645 USPTO (571)
Combinatorial Chemistry Advanced Medicinal Chemistry (Pharm 5219): Section A Ref.: An Introduction to Medicinal Chemistry, 3 rd ed. 2005, G.L.Patrick,
Patentability of Reach-Through Claims Brian R. Stanton Practice Specialist Technology Center 1600 (703)
Combinatorial Chemistry. Synthesis of many structures (diversity) combinatorial technology, combinatorial library molecular diversity What is Combinatorial.
Patentability Considerations in the 3-D Structure Arts Patentability Considerations in the 3-D Structure Arts Michael P. Woodward Supervisory Patent Examiner.
Trilateral Project WM4 Report on comparative study on Examination Practice Relating to Single Nucleotide Polymorphisms (SNPs) and Haplotypes. Linda S.
1 Demystifying the Examination of Stem Cell-Related Inventions Remy Yucel, Ph.D. Supervisory Patent Examiner Technology Center 1600 United States Patent.
Examining Claims for Compliance with 35 U.S.C. 112(a): Part II – Enablement Focus on Electrical/Mechanical and Computer/Software-related Claims August.
FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice Julie Burke TC1600 Quality Assurance Specialist
UNITED STATES PATENT AND TRADEMARK OFFICE
Vector Claims in Gene Therapy Applications: In vivo vs. In vitro Utilities Deborah Reynolds SPE GAU
Introduction Over the last decade, solid phase synthesis and combinatorial chemistry have undergone major evolution. In the early years, the process of.
Patenting Interfering RNA John LeGuyader – SPE Art Unit 1635 (571)
How to Claim your Biotech- Based Invention Deborah Reynolds Detailee, TCPS
1 Enablement Issues in Pharmaceutical Claims Joseph K. M c Kane Supervisory Patent Examiner Art Unit Ardin Marschel Supervisory Patent.
Examination Practice in Applications Presenting “Reach-Through Claims” George Elliott Practice Specialist Technology Center 1600
1 FY08 Restriction Petition Update and Burden Julie Burke Quality Assurance Specialist Technology Center 1600.
Molecular Modeling in Drug Discovery: an Overview
Page 1 Computer-aided Drug Design —Profacgen. Page 2 The most fundamental goal in the drug design process is to determine whether a given compound will.
Ram R. Shukla, Ph.D. SPE AU 1632 & 1634 Technology Center
Patentability Issues and Mechanism Claims
Global Innovation Management Workout on Writing a Patent
Combinatorial chemistry
A tutorial and update on patentable subject matter
Examination Practice in Applications Presenting “Reach-Through Claims”
Examination Issues: Immunology
Presentation transcript:

Combinatorial Technology Supervisory Patent Examiner Jyothsna Venkat Supervisory Patent Examiner Art Unit 1627 (703) 308-2439 jyothsna.venkat@uspto.gov

Art Unit 1627 Bennett Celsa Maurie Garcia Grace Hsu Padmashri Ponnaluri Thomas Prasthofer Theresa Wessendorf

The Evolution of Combinatorial Technology Dates of appearance in the literature... 1985 - Peptide & oligonucleotide libraries 1992 - Small organic molecules 1995 - Superconductors 1997 - Luminescent compounds 1998 - Catalysts 20?? - Convergence with genomics

What Is “Combinatorial” Chemistry? “The chemical or enzymatic synthesis of a very large number of different molecules coupled with a screening technique…” Ecker et al. US 5,474,253, 1995 “Methods for the efficient synthesis and screening of libraries of related compounds with well defined levels of diversity” Ellman et al. PNAS, 1997

What Is “Combinatorial” Chemistry? “A new subfield of chemistry with the goal of synthesizing very large numbers of chemical entities by condensing a small number of reagents together in all combinations defined by a given reaction sequence” Czarnik and DeWitt A Practical Guide to Combinatorial Chemistry, 1997

What Is “Combinatorial” Chemistry? “This field is so new that even the basic terminology is not defined” Lebl, M. J. Comb. Chem., 1999

What Is a “Combinatorial” Library? “An intentionally created collection of differing molecules which can be prepared either synthetically or biosynthetically” Gallop et al. J. Med. Chem., 1994 “A combinatorial library can be defined as any ensemble of molecules” Janda, K. D. PNAS, 1994

“Combinatorial” Absent evidence to the contrary, it is merely a process limitation similar to the term “recombinant”. Clarity in drafting the specification and claims is essential!

Terminology Used in Combinatorial Chemistry In combinatorial technology there is no good set of terms that can cover every scenario. Commonly seen terminology: “combinatorial”, “library”, “collection”, “plurality”, “array”, “linker”, “resin”, “bead”, “diversity”, “tag”, “solid support/supported”, “high-throughput”, “iterative”, “deconvolution”... this is by no means an exhaustive list!

Issues under 35 USC 112 As a library is a collection of components, it is therefore distinguished from a traditional Markush group. Amendments canceling library components may lead to new matter rejections, unless there is original support for the collection as amended.

Issues under 35 USC 112 Enablement Example 1 Claim: A combinatorial library of compounds of formula Q-R in which R is a ligand that inhibits a target receptor and Q is a functional group.

Claim: A combinatorial library of compounds of formula Q-R in which R is a ligand that inhibits a target receptor and Q is a functional group. Specification teaches only libraries with specific R moieties having binding properties to a particular receptor and specific Q moieties. Will probably result in rejection under 35 USC 112, first paragraph for scope of enablement (applicant enabled for specific moieties taught above).

Issues under 35 USC 112 Important Points Specification must set forth the “core” on which a library is built. The core structure of the library that is described must bear some reasonable correlation to the scope of the claims.

Issues under 35 USC 112 Enablement Example 2 Claim: A combinatorial library of dihydropyridine compounds of formula (I): wherein R1, R2 and R3 are independently selected from the group consisting of...

Claim: A combinatorial library of dihydropyridine compounds of formula (I): wherein R1, R2 and R3 are independently selected from the group consisting of... Specification teaches libraries containing various functionalized compounds of formula (I) that are inhibitors of a particular receptor. Will probably NOT result in rejection under 35 USC 112, first paragraph.

Is Claim 3 Properly Dependent? Claim Dependency Claim 1. A compound of formula x-a, wherein a is selected from the group consisting of . . . Claim 2. A combinatorial library comprising two or more compounds of formula x-a as set forth in claim 1. Claim 3. A compound of formula x-a as set forth in claim 1, which is a combinatorial library. Is Claim 3 Properly Dependent?

Claim Dependency Claim 1 is a short hand of claiming a number of variations of a single compound of formula x-a. Claim 3 is a short hand way of claiming a collection of compounds en masse or as an ensemble and is NOT properly dependent.

Another Scenario Claim 1. A combinatorial library comprising two or more compounds of formula x-a. Claim 2. A compound of formula x-a selected from the library of claim 1. Is Claim 2 Properly Dependent? Most Likely

Utility - 35 USC 101 A Library/Mixture/Collection must have a specific, substantial and credible utility An example, covering the scope of the invention, goes a long way in avoiding potential utility problems. According to case law and current USPTO utility guidelines...basic research such as using a material in a method for studying the properties of the material itself or the mechanisms in which the material is involved, is not a specific and substantial utility.

Utility - 35 USC 101 Utility Example Consider the previous claim... Claim: A combinatorial library of dihydropyridine compounds of formula (I): wherein R1, R2 and R3 are independently selected from the group consisting of...

Assuming no well-established utility exists for such compounds then… Claim: A combinatorial library of dihydropyridine compounds of formula (I): wherein R1, R2 and R3 are independently selected from the group consisting of... Specification teaches libraries of compounds of formula (I) can be screened for biological activity. Assuming no well-established utility exists for such compounds then… Will probably result in rejection under 35 USC 101.

Utility - 35 USC 101 HOWEVER If specification teaches libraries of compounds of formula (I) can be screened for a specific activity and/or provides an example of screening the libraries and identifying a compound having a particular activity... Will probably NOT result in rejection under 35 USC 101.

Clarity in Drafting the Disclosure and Claims is Essential!

Anticipation and Obviousness Do “art known” collections/compositions read on “combinatorial libraries”? YES The products/compositions are the same regardless of the manner in which they are prepared.

A case for prima facie obviousness 1. If the parent molecule in a series is known; and 2. The substituents and the substitution pattern claimed are established in the prior art, then 3. Motivation to make the library becomes the question.

Motivation Libraries of (bio)chemical entities “The goals of combinatorial organic synthesis are to create populations of molecular structures” in order to search them for more potent derivatives of known pharmacophores. Gordon et al. J. Med. Chem., 1994

Motivation Libraries of inorganic compounds The fact that properties rely on a number of variables “precludes the truly rational design…and provides a clear invitation to use the power of combinatorial chemistry to accelerate discovery”. Francis et al. “Combinatorial libraries of transition-metal complexes, catalysts and materials”, Cur. Opin. Chem. Biol., 1998

Thank You

Combinatorial Technology Supervisory Patent Examiner Jyothsna Venkat Supervisory Patent Examiner Art Unit 1627 (703) 308-2439 jyothsna.venkat@uspto.gov